{
    "organizations": [],
    "uuid": "9c64714dbd12d2ce8d1e1704cc64ccb0881641f0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bayer-disagrees-with-efsas-updated/brief-bayer-disagrees-with-efsas-updated-risk-assessment-conclusions-for-imidacloprid-and-clothianidin-idUSFWN1QI0UZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Bayer Disagrees With EFSA’S Updated Risk Assessment Conclusions For Imidacloprid And Clothianidin‍​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 28 (Reuters) - BAYER AG:\n* BAYER -FUNDAMENTALLY DISAGREES WITH EFSA’S UPDATED RISK ASSESSMENT CONCLUSIONS FOR ACTIVE SUBSTANCES IMIDACLOPRID AND CLOTHIANIDIN‍​\n* BAYER - WILL CONTINUE TO WORK WITH FARMERS, BEEKEEPERS AND REGULATORS ON SOLUTIONS THAT HAVE POSITIVE IMPACT ON BEE HEALTH Source text - bit.ly/2oBjpL1 Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-28T19:11:00.000+02:00",
    "crawled": "2018-03-01T21:12:58.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "bayer",
        "ag",
        "bayer",
        "disagrees",
        "efsa",
        "updated",
        "risk",
        "assessment",
        "conclusion",
        "active",
        "substance",
        "imidacloprid",
        "bayer",
        "continue",
        "work",
        "farmer",
        "beekeeper",
        "regulator",
        "solution",
        "positive",
        "impact",
        "bee",
        "health",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}